KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $4.4 million.

  • Nektar Therapeutics' Depreciation & Amortization (CF) fell 80.26% to $196,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 79.55%. This contributed to the annual value of $4.4 million for FY2024, which is 43.81% down from last year.
  • Nektar Therapeutics' Depreciation & Amortization (CF) amounted to $4.4 million in FY2024, which was down 43.81% from $7.8 million recorded in FY2023.
  • Nektar Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $14.2 million during FY2020, with a 5-year trough of $4.4 million in FY2024.
  • For the 3-year period, Nektar Therapeutics' Depreciation & Amortization (CF) averaged around $8.4 million, with its median value being $7.8 million (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first grew by 7.80% in 2020, then slumped by 43.81% in 2024.
  • Nektar Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $14.2 million in 2020, then fell by 0.25% to $14.1 million in 2021, then declined by 7.89% to $13.0 million in 2022, then plummeted by 40.02% to $7.8 million in 2023, then tumbled by 43.81% to $4.4 million in 2024.